Academy of Aesthetic Sciences, via Raffaele Morghen 88, 80129, Naples, Italy.
Clinica Grimaldi, S. Giorgio a Cremano, Naples, Italy.
Aesthetic Plast Surg. 2020 Jun;44(3):919-926. doi: 10.1007/s00266-019-01579-z. Epub 2019 Dec 12.
There is a relative lack of evidence on optimal products and techniques for nose treatment with hyaluronic acid (HA) fillers. This study assessed the efficacy and safety of nasal reshaping with Vycross HA fillers, using a free software (Face Master) to measure facial parameters.
This was a prospective, open-label, single-center study of consecutive adult patients treated in the nose (bony and cartilaginous dorsum and/or columella) with VYC-20 or VYC-17.5. A maximum of 1 mL of filler was used. All patients (except one) had at least 12 months of follow-up.
Sixty-two patients were enrolled (57 females; 5 males) with a mean age of 29.0 ± 9.2 years. A mean of 0.55 ± 0.22 mL of filler (range 0.2-1.0 mL) was injected during initial treatment; 12 patients required touch-up with 0.15 ± 0.08 mL of filler (range 0.1-0.3 mL). Using Face Master, mean nasofrontal angle increased from 143.6 ± 6.3° pre-treatment to 147.3 ± 6.7° post-treatment (mean change 3.7 ± 2.8°), and mean nasolabial angle increased from 85.3 ± 6.1° to 88.5 ± 6.1° (mean change 3.2 ± 2.6°). Mean patient satisfaction (0-10 scale) increased from 2.4 ± 1.7 pre-treatment to 9.4 ± 0.8 post-treatment (mean improvement 7.1 ± 2.1). Complications were minor and transient: pain, n = 3 (4.8%); edema, n = 3 (4.8%); hematoma, n = 2 (3.2%).
Non-surgical nasal reshaping with VYC-20 or VYC-17.5 appeared to be efficacious and safe; Face Master objectively demonstrated meaningful changes in key nasal angles.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
在使用透明质酸（HA）填充物进行鼻部治疗方面，最佳产品和技术的证据相对较少。本研究使用免费软件（Face Master）测量面部参数，评估 Vycross HA 填充物进行鼻整形的疗效和安全性。
这是一项连续的、前瞻性、开放性、单中心研究，纳入在鼻部（骨性和软骨性鼻背和/或鼻中隔）接受 VYC-20 或 VYC-17.5 治疗的成年患者。每个患者最多注射 1 毫升填充物。除 1 例患者外，所有患者均随访至少 12 个月。
共纳入 62 例患者（57 例女性；5 例男性），平均年龄 29.0±9.2 岁。初次治疗时，平均注射 0.55±0.22 毫升填充物（范围 0.2-1.0 毫升）；12 例患者需要进行补注，注射 0.15±0.08 毫升填充物（范围 0.1-0.3 毫升）。使用 Face Master，鼻额角从治疗前的 143.6±6.3°增加到治疗后的 147.3±6.7°（平均变化 3.7±2.8°），鼻唇角从 85.3±6.1°增加到 88.5±6.1°（平均变化 3.2±2.6°）。患者满意度（0-10 分）从治疗前的 2.4±1.7 分增加到治疗后的 9.4±0.8 分（平均改善 7.1±2.1 分）。并发症轻微且短暂：疼痛 3 例（4.8%）；水肿 3 例（4.8%）；血肿 2 例（3.2%）。
使用 VYC-20 或 VYC-17.5 进行非手术性鼻部重塑似乎是有效且安全的；Face Master 客观地证明了关键鼻部角度的显著变化。
证据等级 IV：本杂志要求作者为每篇文章分配一个证据等级。有关这些循证医学评级的完整描述，请参考目录或在线作者指南 www.springer.com/00266。
